DILIsym Services, Inc. (DSS), a Simulations Plus company, improves the safety and efficacy of new therapeutics by utilizing their proprietary DILIsym® and NAFLDsym® software, respectively. These quantitative systems models are used to predict and understand the responses to treatment, including non-alcoholic fatty liver disease (NAFLD). Simulation results are used to optimize clinical trial protocols, inform candidate selection, guide risk-benefit decisions, identify personalized medicine approaches, and support regulatory communications.
As a division of BioTelemetry, Inc. (Nasdaq: BEAT), leaders in remote health monitoring, we provide expert imaging and cardiac core lab solutions for the advancement of biopharmaceutical development worldwide. Our organization monitors hundreds of thousands of patients and study subjects per year, while supporting approximately 20,000 sites and provisioning 30,000 devices monthly. We offer global operational support for… Read more
Organovo develops dynamic, multi-cellular, and fully-human tissues that closely model native architecture and biology. With the NovoGen Brioprinter® Platform, the Company designs tissues for use in applications spanning pre-clinical safety testing, disease modeling, and regenerative medicine. Tissues are commercially available through its NovoView™ Service Offering and through strategic partnerships… Read more